Edgewise Therapeutics, Inc. (EWTX) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
7.25
↑+119% vs avg
5yr avg: 3.32
30Y Low1.4·High5.4
ROE
↑
-34.2%
-10% vs avg
5yr avg: -31.2%
30Y Low-36%·High-22%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EWTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Edgewise Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.0B | $2.6B | $2.5B | $697M | $479M | $756M | — | — |
| Enterprise Value | $3.9B | $2.5B | $2.4B | $616M | $462M | $741M | — | — |
| P/E Ratio → | -22.58 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 7.25 | 4.89 | 5.37 | 2.19 | 1.38 | 2.76 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EWTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
EWTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -34.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -34.2% | -34.2% | -34.4% | -30.1% | -21.8% | -35.5% | — | — |
| ROA | -32.3% | -32.3% | -32.4% | -28.3% | -20.7% | -20.6% | -21.9% | -38.7% |
| ROIC | -32.4% | -32.4% | -36.1% | -30.2% | -18.3% | -23.1% | — | — |
| ROCE | -38.7% | -38.7% | -40.4% | -33.9% | -22.9% | -21.5% | -22.9% | -42.4% |
EWTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $61M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.11 | -0.08 | -0.25 | -0.05 | -0.06 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -17.83 | — | — | — |
Net cash position: cash ($61M) exceeds total debt ($4M)
EWTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Edgewise Therapeutics, Inc.'s current ratio of 19.85x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 19.50x to 19.85x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 19.85 | 19.85 | 19.93 | 19.50 | 21.53 | 26.97 | 29.86 | 21.24 |
| Quick Ratio | 19.85 | 19.85 | 19.93 | 19.50 | 21.53 | 26.97 | 29.86 | 21.24 |
| Cash Ratio | 19.37 | 19.37 | 19.71 | 18.98 | 21.22 | 26.69 | 29.73 | 20.89 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
EWTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Edgewise Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $103M | $92M | $64M | $54M | $50M | $49M | $49M |
Peer Comparison
Compare EWTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EWTXYou | $4B | -22.6 | — | — | — | — | -34.2% | -32.4% | — |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 KYMR | $7B | -24.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 CMPS | $1B | -4.1 | — | — | — | — | -565.3% | — | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 ARQT | $3B | -201.6 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 PRAX | $8B | -20.9 | — | — | — | — | -45.8% | -65.0% | — |
 MGTX | $1B | -8.0 | — | — | 94.0% | -130.2% | -368.2% | -241.1% | — |
 MDGL | $12B | -39.4 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 URGN | $2B | -10.5 | — | — | 88.7% | -113.7% | — | — | — |
 TMDX | $3B | 16.2 | 19.9 | 20.4 | 59.9% | 17.9% | 54.2% | 18.8% | 3.5 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
EWTX — Frequently Asked Questions
Quick answers to the most common questions about buying EWTX stock.
What is Edgewise Therapeutics, Inc.'s P/E ratio?
Edgewise Therapeutics, Inc.'s current P/E ratio is -22.6x. This places it at the 50th percentile of its historical range.
What is Edgewise Therapeutics, Inc.'s ROE?
Edgewise Therapeutics, Inc.'s return on equity (ROE) is -34.2%. The historical average is -31.2%.
Is EWTX stock overvalued?
Based on historical data, Edgewise Therapeutics, Inc. is trading at a P/E of -22.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.